Login to Your Account



Other News To Note


Wednesday, September 26, 2012
• Aprea AB, of Stockholm, Sweden, reported positive data from a Phase I/II study with investigational drug APR-246. In the trial, escalating doses of APR-246 were administered as a monotherapy to 22 patients with advanced blood or prostate cancer for up to four consecutive days. Dose-limiting toxicity was shown at plasma levels well above predicted therapeutic plasma levels.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription